Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.But in recent weeks, Vertex stock has declined, and last week it lost nearly 12% in one trading session after an element from a clinical trial report disappointed investors. Meanwhile, Vertex is heading for two pieces of news in January that could be enormous for the company.Should you take advantage of recent losses to buy Vertex on the dip before the new year? Or is the recent clinical trial news a warning for investors? Let's find out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool